BioNTech SE (BNTX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $89.83, BioNTech SE (BNTX) is priced for +8.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-24.

Generated: 2026-07-24 · Exported: 2026-07-25 · Source: https://boothcheck.com/report/BNTX

Headline

FieldValue
TickerBNTX
CompanyBioNTech SE
Sector / IndustryHealthcare
Current price$89.84/sh
CompositionCOVID-19 vaccine revenues 70% / Revenues from out-licensing 21% / Other revenues 9%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid4.3x
Steady-state operating margin assumed33.6%
Implied growth8.3%

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 10.3% cost of capital with 4% terminal growth over a 5-year stage, holding a 33.6% terminal operating margin (84% gross margin x the 40% mature-conversion prior); each 1pp of cost of capital moves the implied revenue growth ~5.6pp.

Reconcile: at the x-ray's 9.3% required return this reads ~2.5%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history-0.46σ
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power value, while relative-multiple/growth-DCF land below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.10x2expensive
Earnings1.18x2expensive
Relative1.74x2expensive
Growth2.32x2expensive

Families that justify the price: Asset, Earnings Families that call it expensive: Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=8)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$42.282.12xyesFCF base $0.3B, growth -10% (input: historical growth), terminal g 0.5%, WACC 9.2%, 5yr projection
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$51.631.74xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$86.451.04xyesReference only (book value floor): BV/sh $86.45, ROE negative
Two-Stage Excess ReturnAsset$77.811.15xyesReference only (book value with convergence): BV/sh $86.45, ROE converges to ke
Discounted Future Market CapGrowth$35.822.51xyesRev $3.1B, growth -15% (input: historical growth; tapered), Terminal P/S: 5.8x / 7.0x / 8.1x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$230.910.39xyesNormalized EBIT (5y avg op income, one-time charges added back) $5.63B × (1−21%) / WACC 9.2% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings$45.381.98xyesFCF $305.3M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$51.631.74xyesRevenue $3.12B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$8.7b
Interest coverage-98.9x
Share count CAGR (buyback)-0.2%
Burning cashno

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

Strip out the pipeline and what remains is a very large bank account. Cash, cash equivalents and security investments stood at €16.8 billion on March 31, 2026, against a market value in the low twenty billions of dollars. Over the quarter that pile fell by roughly half a billion euros, which is about the size of the loss it funded. A company can be wrong for a long time on that footing without ever having to ask anyone for money, and that is where the bull case starts.

What the money is buying is pumitamig, the bispecific antibody carried until recently as BNT327. Bristol Myers Squibb agreed to co-develop and co-commercialise it, and under the amended agreement pays a $1.5 billion upfront plus $2.0 billion of non-contingent anniversary payments through 2028, with up to $7.6 billion of development, regulatory and commercial milestones beyond that and global profits and losses split evenly. Two things follow. One is validation: a partner with among the deepest oncology commercial organisations in the industry looked at the same data and paid for half of it. The other is arithmetic: the most expensive programme in the pipeline now costs BioNTech half of what it otherwise would, and the anniversary money arrives whether or not any given trial reads out well.

Development has moved past the slide stage. Five pivotal global studies opened in the first quarter of 2026 alone, covering triple-negative breast cancer, microsatellite-stable colorectal cancer, gastric cancer and two separate non-small-cell lung populations, and randomised Phase 2 data from the ongoing ROSETTA Lung-02 study is expected at this year's ASCO meeting. Broad, funded and partnered is a different risk profile from broad and self-financed.

The cost base is finally being cut to fit the company that exists rather than the one that existed in 2021. Management is exiting manufacturing sites at Idar-Oberstein, Marburg and Singapore along with acquired CureVac facilities, affecting roughly 1,860 positions and targeting about €500 million of recurring annual savings once fully implemented in 2029. Building pandemic-scale capacity was rational when the world wanted a billion doses. Carrying it against guided 2026 revenue of €2.0 billion to €2.3 billion is not.

Capital return has started as well. The boards expect to authorise up to $1.0 billion of ADS repurchases over the twelve months from May 2026. For a business carrying no borrowings worth the name, that is management saying it would rather own its own shares than another tranche of German government paper.

The bear's central point, that the operating business consumes money faster than any product can currently replace it, is simply true and no bull should pretend otherwise. The answer is that the balance sheet buys enough time for the clinical question to be settled, and that a settled yes is worth considerably more than a bank account.

Bear Case

The price is a bet that the bank account turns into a pharmaceutical company. At $89.84, revenue has to grow at roughly 8.3% a year for the arithmetic to hold together, and that arithmetic carries a steady-state operating margin of about 33.6%. What the business runs today is an operating margin of about -49%. The distance between those two figures is the entire argument, and everything else is a theory about how it closes.

Start with what is shrinking. COVID-19 vaccine sales still account for 70% of trailing revenue, and first-quarter 2026 revenues came in at €118.1 million against €182.8 million a year earlier. Full-year guidance of €2.0 billion to €2.3 billion is not a recovery in that franchise. A large part of it is money Bristol Myers Squibb has already contracted to pay, and the company expects 2026 collaboration revenue to run broadly in line with 2025.

Now set the spending beside it. Adjusted research and development for 2026 is guided at €2.2 billion to €2.5 billion, with adjusted selling, general and administrative expense at €700 million to €800 million. Against that revenue range, the plan is to spend roughly a billion euros more than the company takes in, before any restructuring charges. The first quarter executed the plan precisely: an operating loss of €677.5 million and a net loss of €531.9 million.

The balance sheet is real but it is not inert. It is the fuel for exactly this burn, and it is being spent deliberately. The repurchase authorisation spends more of it, which is sound capital allocation if the shares are cheap and a permanent reduction in the downside floor if they are not. Who benefits and who pays depends entirely on a clinical result nobody has yet seen.

Then there is the science, which is where the money goes and where the answer lives. Pumitamig pairs PD-L1 and VEGF blockade in a single molecule, an approach that has drawn one of the largest concentrations of competing programmes in oncology, and BioNTech opened five pivotal trials across four tumour types in a single quarter. Breadth of that kind cuts both ways. It maximises the value of a positive result, and it commits the spending before any controlled outcome is known. The first randomised readout is still ahead of the company, not behind it.

One accounting point deserves separating out, because it flatters every backward-looking comparison. BioNTech's own profitability history contains 2021 and 2022. Any measure of normalised earning power built on a five-year average is averaging in a pandemic that will not repeat, and a reader who anchors on it will conclude the company is far more profitable than the one being funded today. On its own products, outside that window, the business has never earned a profit at all. The price assumes it eventually earns one at pharmaceutical-industry margins, and rarely has so much of a large-cap valuation rested on a molecule still awaiting its first controlled result.

Valuation

The methods split here, and the way they split is the information.

Asset-value methods land closest. The price sits only about 10% above where those methods put the company, and the reason is that BioNTech's book is overwhelmingly liquid rather than industrial. Cash, cash equivalents and security investments were €16.8 billion at March 31, 2026, made up of €9,939.4 million of cash and equivalents, €4,696.9 million of current security investments and €2,127.0 million of non-current security investments. A buyer at today's price is paying roughly what the balance sheet already holds and taking the pipeline as the variable.

Peer-multiple methods sit further away: the price is about 74% above where those methods land. That read deserves a caveat, because with no earnings to work from it is a sales-multiple stand-in rather than a comparison of like businesses. The forward cash-flow methods are furthest of all, roughly 2.3 times where those methods land, and the mechanism there is straightforward: they project forward from a revenue base that has been falling, which is what a receding pandemic franchise does to a discounted cash-flow model.

The one family that appears to reach the price does not really. The two earnings-power methods point in opposite directions. One capitalises a five-year average of operating income that still contains the pandemic years and lands far above the price; the other capitalises last year's modest free cash flow and lands far below it. Their midpoint averages two answers to different questions, and it should not be read as agreement.

The price assumes revenue grows at roughly 8.3% a year. The arithmetic behind that carries a steady-state operating margin of about 33.6%, which is a held assumption derived from gross profitability rather than anything the company has demonstrated at scale; against a trailing operating margin near -49%, it is a long way from the evidence. Read plainly, that is an assumption about what BioNTech becomes, not a description of what it is.

Solvency barely needs a paragraph. The company reported €56.7 million of current and €246.1 million of non-current lease liabilities, loans and borrowings at March 31, 2026, which does not constrain anything. Share count has been essentially flat over the past four years, so no part of the story is dilution. The binding constraint is the burn rate against the pile, and on the 2026 plan the pile funds the plan for years rather than quarters. What that buys is time to find out, which for a company at this stage is the only thing money can buy.

Catalysts

The next scheduled information event is August 4, 2026, when BioNTech reports second-quarter results and provides a corporate update. Two lines matter more than the headline. The first is the revenue split, since contracted collaboration payments and actual product sales behave nothing alike. The second is the pace of research spending against the €2.2 billion to €2.5 billion adjusted guidance, which sets how quickly the balance sheet converts into clinical data.

The clinical calendar carries more weight than the financial one. Randomised Phase 2 data from ROSETTA Lung-02 is expected at this year's ASCO annual meeting, the first controlled look at pumitamig in lung cancer. The five pivotal studies opened during the first quarter of 2026, spanning triple-negative breast, microsatellite-stable colorectal, gastric and two non-small-cell lung populations, are enrolment events for now; their outcomes sit beyond this year.

Two structural items run on their own clocks. The $2.0 billion of non-contingent anniversary payments from Bristol Myers Squibb continues through 2028, so a meaningful slice of near-term revenue is contractual rather than commercial. And the manufacturing consolidation, covering site exits at Idar-Oberstein, Marburg and Singapore plus acquired CureVac facilities and roughly 1,860 positions, targets about €500 million of recurring annual savings by 2029. That programme shows up as charges first and savings later, so the near-term prints will look worse than the run rate it is building toward.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

BioNTech Q1 2026 results, May 5, 2026 · BioNTech Q1 2026 corporate update, May 5, 2026 · BioNTech Q1 2026 and full-year 2025 results · BioNTech and Bristol Myers Squibb amended partnership agreement, August 15, 2025 · BioNTech press release, July 21, 2026

View the full interactive BNTX report on boothcheck